Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance

被引：46

作者：

An, Ping ^{[1
]}

Thio, Chloe L. ^{[2
]}

Kirk, Gregory D. ^{[3
]}

Donfield, Sharyne ^{[5
]}

Goedert, James J. ^{[4
]}

Winkler, Cheryl A. ^{[1
]}

机构：

[1] Sci Applicat Int Corp, Lab Genom Divers, Frederick, MD USA

[2] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA

[3] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[4] NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA

[5] Rho Inc, Chapel Hill, NC USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2008年 / 198卷 / 08期

关键词：

D O I：

10.1086/592047

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The immune response is critical in determining the outcome of hepatitis C virus (HCV) infection. Interleukin (IL)-18 is a pivotal mediator of the Th1/Th2-driven immune response. Two IL-18 promoter polymorphisms (-607C/A and -137G/C) and their haplotypes were known to affect IL-18 expression. We examined the role played by these polymorphisms in determining HCV clearance or persistence. Genotyping was performed among African American injection drug users with HCV clearance (n = 91) or HCV persistence ( n = 182) and among European Americans with hemophilia who were mainly infected through plasma transfusion. Among injection drug users, IL18 -607A (odds ratio [OR], 3.68 [95% confidence interval{CI}, 1.85-7.34]) and IL18 -137C ( OR, 2.33 [95% CI, 1.24-4.36]) were significantly associated with HCV clearance. A haplotype carrying -607A and -137C (OR, 4.53 [95% CI, 1.77-11.6]) was also strongly associated with viral clearance. No association was found among those with hemophilia. These results suggest that IL-18 promoter polymorphism may affect the outcome of HCV infection in certain groups.

引用

页码：1159 / 1165

页数：7

共 44 条

[41] Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users -: Plasma viral load and CD4+ cell count [J].

Vlahov, D ;

Graham, N ;

Hoover, D ;

Flynn, C ;

Bartlett, JG ;

Margolick, JB ;

Lyles, CM ;

Nelson, KE ;

Smith, D ;

Holmberg, S ;

Farzadegan, H .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (01) :35-40

[42]

Zhang PA, 2005, WORLD J GASTROENTERO, V11, P1594, DOI 10.3748/wjg.v11.i11.1594

[43] The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells [J].

Zheng, WP ;

Flavell, RA .

CELL, 1997, 89 (04) :587-596

[44]

Zhou YQ, 2005, SARCOIDOSIS VASC DIF, V22, P105

← 1 2 3 4 5 →